wellness

Nature Medicine, Published online: 15 September 2024; doi:10.1038/s41591-024-03250-w

In the phase 2 NICHE-3 trial, patients with locally advanced mismatch repair-deficient colon cancer who were treated with neoadjuvant anti-PD1 and anti-LAG3 agents showed high rates of pathological responses, requiring validation in larger trials.

Nature Medicine, Published online: 14 September 2024; doi:10.1038/s41591-024-03267-1

In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab–deruxtecan plus durvalumab, followed by sequential chemotherapy with or without targeted therapy, with the option of early surgical resection after each block of therapy, showing that de-escalation of therapy is possible for several patient subgroups without compromising outcome and avoiding toxicity of standard chemotherapy.

Nature Medicine, Published online: 14 September 2024; doi:10.1038/s41591-024-03266-2

In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab–deruxtecan, followed by sequential chemotherapy with or without targeted therapy, with the option of early surgical resection after each block of therapy. In a subgroup of patients, the sequential treatment strategy was superior to standard of care.

Nature Medicine, Published online: 13 September 2024; doi:10.1038/s41591-024-03261-7

In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients with HER2+ advanced breast cancer and active or stable brain metastases showed consistent intracranial activity and systemic efficacy of T-DXd.

Nature Medicine, Published online: 13 September 2024; doi:10.1038/s41591-024-03241-x

Post-approval evidence generation is essential for high-quality clinical care and should be a shared priority for clinicians, health systems, payors, and the medical products industry, as well as the FDA and federal agencies.

Nature Medicine, Published online: 13 September 2024; doi:10.1038/s41591-024-03217-x

A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of ‘personalized’ therapies for rare diseases; but pathways to implementation and access are urgently needed.

Nature Medicine, Published online: 12 September 2024; doi:10.1038/s41591-024-03247-5

In a first-in-human trial of a triple combination of broadly neutralizing antibodies in people living with HIV, 83% of participants maintained virologic suppression for the duration of antibody therapy, with 42% showing virologic suppression for at least 38–44 weeks, despite the decline of serum antibody concentrations to low or undetectable levels.

Nature Medicine, Published online: 12 September 2024; doi:10.1038/s41591-024-03214-0

Incorporating a series of analytical steps, from data extraction and quality control to the generation of low-dimensional representations and to longitudinal analyses, an open-source software is proposed to standardize current electronic health record data processing and analysis pipelines.

Nature Medicine, Published online: 12 September 2024; doi:10.1038/s41591-024-03246-6

The European Health Data Space provides an opportunity to benefit patients and the public.

Nature Medicine, Published online: 12 September 2024; doi:10.1038/d41591-024-00069-3

In people undergoing medical abortion after 12 weeks of pregnancy, those who took the first dose of misoprostol at home were less likely to require overnight hospitalization.